Global Aspiration & Biopsy Needles Market to See Strong Growth

According to a recently released report from market research company Research and Markets, the global aspiration and biopsy needles market is poised for solid growth over the next five years. The report values the market at an estimated $879 million US for 2021, and projects it will reach $1.3 billion US in 2027, constituting a compound annual growth rate (CAGR) of 6.8 percent.

The Aspiration & Biopsy Needles Market

Aspiration and biopsy needles are used to remove tumor samples from patients for diagnosis of various cancers, as well as diagnosing wound infections and other clinical applications. There are two basic kinds of cancer needle biopsies:

• Fine needle biopsy (also called fine needle aspiration, or FNA) uses a very thin, hollow needle attached to a syringe that the doctor can directly aim or guide via ultrasound or CT scan to extract a small amount of fluid and very small pieces of tissue; and
• Core needle biopsy (also called core biopsy) uses a slightly larger needle to remove a small cylinder of tissue (about 1/16 inch in diameter and 1/2 inch long).

The main advantage of FNA is that the skin doesn’t have to be cut; and in some cases, it’s possible to make a diagnosis the same day. By contrast, core needle biopsy is done with local anesthesia (drugs are used to make the area numb) in the doctor’s office or clinic.

Drivers & Patterns of Market Growth

The report suggests that growth in the biopsy and aspiration needles market will be driven by two crucial factors:

• Rising cancer rates; and
• Patients’ preferences for minimally-invasive diagnostic procedures.

Products serving hospital and surgical center group end users are expected to grow at the highest rates over the next five years. And to the extent that hospitals and surgical center groups frequently use biopsy needles, the report predicts that this segment will grow faster than aspiration needles. Other end users for both types of needles include research and academic institutes, diagnostic clinics, pathology labs and ambulatory care centers. In terms of clinical application, the report notes that the breast cancer segment held the largest share of the aspiration and biopsy needle market in 2020 and that this will likely continue for the foreseeable future due to rising breast cancer rates, greater volume of research being done in this area, and increasing breast cancer awareness. The report adds that high cancer rates, research growth, and cancer screening and diagnostics initiatives make it likely that the Asia Pacific market will grow at the highest CAGR over the next five years. Key companies in the aspiration and biopsy needles market include Becton Dickinson, Olympus, Boston Scientific, Medtronic, Stryker, CONMED, Merit Medical Systems, Sterylab, Cook Medical LLC, and Cardinal Health.

6 Things You Should Know about the Aspiration and Biopsy Needles Market

1. It’s expected to reach US $1.29 billion in 2026 2. Core needle biopsy is the most common type of biopsy, accounting for over 47 percent of the market in 2019 3. Hospitals accounted for 74.3 percent of the entire market in 2019 4. North America is the world's largest consumer area, accounting for 35.2 percent of global market sales in 2019 5. Europe is also a significant consumer, accounting for 30.46 percent of 2019 global sales 6. Vacuum-assisted biopsy, biopsy guns, and biopsy forceps and punches will develop at far faster rates than FNA, with CAGRs of, respectively, 3.97 percent, 3.70 percent, and 1.63 percent